Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
China's Stemirna Halts mRNA Cancer Vaccine Trial, Researchers Say
Details : SW1115C3 is a personalized cancer vaccine (PCV) consisting of mRNA encoding a patient's tumor-specific neoantigens. It is being evaluated for the treatment of solid tumors.
Product Name : SW1115C3
Product Type : Vaccine
Upfront Cash : Inapplicable
March 21, 2024
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Tibet Rhodiola Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Stemirna COVID-19 Vaccine Candidate Obtains Clinical Trial Approval in China
Details : The potential vaccine, which Stemirna has started working on since January last year, is based on messenger RNA (mRNA) technology, Tibet Rhodiola Pharma, which is jointly developing the candidate with Stemirna.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 01, 2021
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Tibet Rhodiola Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Sequoia Capital
Deal Size : $200.0 million
Deal Type : Financing
China's Stemirna Raises About $200 Mln to Fund Covid-19 Vaccine Development
Details : Stemirna Therapeutics raised nearly $200 million to speed up the clinical study of its COVID-19 vaccine candidate, SW-0123. It is in phase I study in China and preclinical data have been published in Nature.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 06, 2021
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Sequoia Capital
Deal Size : $200.0 million
Deal Type : Financing
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pilot testing of potential COVID-19 vaccine progresses
Details : The pilot testing of the vaccine for novel coronavirus, will be focused on animal toxicology and the vaccine's effectiveness. Clinical trials are expected to start in mid-April.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable